Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | GRK2 | P25098 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9782150 | 0.81 | NOTUM (1.00) | NOTUMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL789358 | 0.81 | NOTUM (0.68) | NOTUMSORT1 | |
| SCHEMBL22925624 | 0.80 | NOTUM (0.62) | NOTUM | |
| SCHEMBL181974 | 0.80 | NOTUM (0.67) | NOTUMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL31178428 | 0.78 | NOTUM (0.65) | NOTUMMAPTSORT1PDE3BPDE3A | |
| SCHEMBL14373829 | 0.77 | NOTUM (0.62) | NOTUMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL20370831 | 0.77 | NOTUM (0.67) | NOTUMRAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL11023401 | 0.77 | NOTUM (0.62) | NOTUMRAB9ANPC1SORT1 | |
| SCHEMBL40478 | 0.77 | NOTUM (0.62) | NOTUMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11717156 | 0.72 | NOTUM (0.56) | NOTUMSORT1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956220-B2 | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956220-B2 | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956220-B2 | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170137427-A1 | IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137427-A1 | IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137427-A1 | IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-18 | — | — | US | disclosed |
| EP-3157925-A1 | IMIDAZO-PYRIDAZNE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015195880-A1 | IMIDAZO-PYRIDAZNE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015195880-A1 | IMIDAZO-PYRIDAZNE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20120065063-A1 | 3-Aryl-4-(2,6-dimethylbenzylidene)isoxazol-5(4H)-ones as Fungicides | BAYER CROPSCIENCE AG (DE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065063-A1 | 3-Aryl-4-(2,6-dimethylbenzylidene)isoxazol-5(4H)-ones as Fungicides | CYP4X1, CYP4Z1, HAAO | NOTUM 1120/4885POLB 3132/4885APAF1 2540/4885 |
| US-20170137427-A1 | IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | CSNK1A1, CSNK1G1, CSNK1E | NOTUM 3135/4885POLB 1460/4885APAF1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.